



HAL
open science

The Regulatory RNA ern0160 Confers a Potential Selective Advantage to *Enterococcus faecium* for Intestinal Colonization

Sophie Reissier, Killian Le Neindre, Valérie Bordeau, Loren Dejoies, Audrey Le Bot, Brice Felden, Vincent Cattoir, Matthieu Revest

► **To cite this version:**

Sophie Reissier, Killian Le Neindre, Valérie Bordeau, Loren Dejoies, Audrey Le Bot, et al.. The Regulatory RNA ern0160 Confers a Potential Selective Advantage to *Enterococcus faecium* for Intestinal Colonization. *Frontiers in Microbiology*, 2021, 12, pp.757227. 10.3389/fmicb.2021.757227. hal-03512727

HAL Id: hal-03512727

<https://hal.science/hal-03512727>

Submitted on 2 Jun 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License



The Regulatory RNA *ern0160* Confers a Potential Selective Advantage to *Enterococcus faecium* for Intestinal Colonization

Sophie Reissier¹, Killian Le Neindre^{1,2}, Valérie Bordeau¹, Loren Dejoies^{1,2}, Audrey Le Bot^{1,3}, Brice Felden^{1†}, Vincent Cattoir^{1,2*} and Matthieu Revest^{1,3*}

¹ Unité Inserm U1230, Université de Rennes 1, Rennes, France, ² Service de Bactériologie-Hygiène Hospitalière & CNR de la Résistance aux Antibiotiques (Laboratoire Associé 'Entérocoques'), CHU de Rennes, Rennes, France, ³ Service de Maladies Infectieuses et Réanimation Médicale, CHU de Rennes, Rennes, France

OPEN ACCESS

Edited by:

Axel Cloeckert,
Institut National de Recherche pour
l'Agriculture, l'Alimentation et
l'Environnement (INRAE), France

Reviewed by:

Monica Garcia Solache,
Rhode Island Hospital, United States
Charlotte Michaux,
Harvard Medical School,
United States

*Correspondence:

Matthieu Revest
matthieu.revest@chu-rennes.fr
Vincent Cattoir
vincent.cattoir@univ-rennes1.fr

† Deceased

Specialty section:

This article was submitted to
Infectious Agents and Disease,
a section of the journal
Frontiers in Microbiology

Received: 11 August 2021

Accepted: 11 October 2021

Published: 10 November 2021

Citation:

Reissier S, Le Neindre K,
Bordeau V, Dejoies L, Le Bot A,
Felden B, Cattoir V and Revest M
(2021) The Regulatory RNA *ern0160*
Confers a Potential Selective
Advantage to *Enterococcus faecium*
for Intestinal Colonization.
Front. Microbiol. 12:757227.
doi: 10.3389/fmicb.2021.757227

The aim of this study was to evaluate the role of the regulatory small RNA (sRNA) *Ern0160* in gastrointestinal tract (GIT) colonization by *Enterococcus faecium*. For this purpose, four strains of *E. faecium* were used, Aus0004 (WT), an *ern0160*-deleted Aus0004 mutant (Δ 0160), a *trans*-complemented Δ 0160 strain overexpressing *ern0160* (Δ 0160_0160), and a strain Δ 0160 with an empty pAT29 vector (Δ 0160_pAT29). Strains were studied both *in vitro* and *in vivo*, alone and in competitive assays. In *in vitro* experiments, no difference was observed between WT and Δ 0160 strains cultured single while Δ 0160_0160 strain grew more slowly than Δ 0160_pAT29. In competitive assays, the WT strain was predominant compared to the deleted strain Δ 0160 at the end of the experiment. Then, *in vivo* experiments were performed using a GIT colonization mouse model. Several existing models of GIT colonization were compared while a novel one, combining ceftriaxone and amoxicillin, was developed. A GIT colonization was performed with each strain alone, and no significant difference was noticed. By contrast, significant results were obtained with co-colonization experiments. With WT + Δ 0160 suspension, a significant advantage for the WT strain was observed from day 5 to the end of the protocol, suggesting the involvement of *ern0160* in GIT colonization. With Δ 0160_0160 + Δ 0160_pAT29 suspension, the strain with the empty vector took the advantage from day 3 to the end of the protocol, suggesting a deleterious effect of *ern0160* overexpression. Altogether, these findings demonstrate the potential implication of *Ern0160* in GIT colonization of *E. faecium*. Further investigations are needed for the identification of sRNA target(s) in order to decipher underlying molecular mechanisms.

Keywords: *E. faecium*, VRE, sRNA, pathogenicity, animal model, gut colonization

INTRODUCTION

Enterococci are ubiquitous Gram-positive cocci that are normal inhabitants of the human gut microbiota. *Enterococcus faecium*, which represents 15–25% of enterococcal isolates responsible for human infections, has been increasingly involved in healthcare-associated infections and hospital outbreaks (Goh et al., 2017; Weiner-Lastinger et al., 2020). Glycopeptides are usually used to treat

serious *E. faecium* infections, but many clinical isolates have become resistant to vancomycin (VREF) especially in North America. In 2010, up to 80% of VREF were reported in the United States (O'Driscoll and Crank, 2015). According to the European Antimicrobial Resistance Surveillance Network (EARS-Net), the mean proportion of VREF among invasive isolates increased from 10.4 to 17.3% in European countries between 2014 and 2018 (European Centre for Disease Prevention and Control, 2019). These high rates of VREF prevalence could be attributable to the worldwide dissemination of a subpopulation of *E. faecium* hospital-adapted clones that belongs to the clonal complex 17 (CC17) and represents a public health concern (Cattoir and Giard, 2014). This CC17 actually corresponds to the phylogenetic clade A1 composed by the majority of strains responsible for infections and hospital outbreaks. Two other clades also exist, clade A2 that includes animal strains and sporadic human infection isolates and clade B that comprises human commensal fecal strains (Lebreton et al., 2013).

In recent years, bacterial regulatory RNAs, referred to as small RNAs (sRNAs), have been described as having a major role in various adaptive responses, including stress response, virulence, and antimicrobial resistance (Mraheil et al., 2010; Wagner and Romby, 2015; Klein and Raina, 2017). For example, SprX contributes to vancomycin resistance in *Staphylococcus aureus* (Eyraud et al., 2014) and some sRNAs are involved in stress response in *Enterococcus faecalis* (Michaux et al., 2014). Recently, 61 sRNA candidates were identified in *E. faecium* but there are currently no published data about their function (Siné et al., 2017). Among them, 10 have been experimentally validated and their expression under sub-inhibitory concentrations (SICs) of daptomycin was observed. sRNA_0160 (renamed here Ern0160) appeared to be highly expressed and its expression decreased significantly under daptomycin exposure. Furthermore, *ern0160* is conserved in all studied strains of *E. faecium* belonging to the three different clades (Siné et al., 2017). These initial positive results led us to study this sRNA to evaluate its potential role in intestinal colonization.

Because the gastrointestinal tract (GIT) serves as a major reservoir from which VREF can spread to the hospital environment and GIT colonization precedes infection, understanding GIT colonization mechanisms appears to be essential to better manage those infections and to limit VREF hospital spread (Donskey et al., 2000, 2001; Ubeda et al., 2010). *In vivo* GIT colonization experimental models with enterococci have been described for a long time, with about one-third of these studies exploring *E. faecium*. Most of them used mouse models and different antibiotic protocols to eliminate the animal commensal microbiota allowing to the establishment of colonization by the studied bacteria. Several different protocols for GIT colonization with enterococci have been published, and there is no consensus on molecules used as well as routes and durations of administration. For example, Heikens et al. (2009) used a protocol with subcutaneous (SC) ceftriaxone alone, administered for 12 days. Zhang et al. (2013) associated SC ceftriaxone 2 days before inoculation, with cefoxitin added to drinking water (DW) during the protocol. Montealegre et al. (2016) published in 2016 a model of *E. faecium* GIT colonization

using a combination of SC clindamycin and gentamicin in DW only 4 days before inoculation. As these protocols are very different, it seemed interesting to compare their performances. Moreover, as VREF intestinal colonization mostly occurs in patients treated with broad-spectrum antibiotics, it seems important to use antibiotics frequently prescribed in clinics, such as third-generation cephalosporins or ampicillin, to study the mechanisms of VREF colonization (Dubin and Pamer, 2014).

The aim of this study was to evaluate the role of Ern0160 in *E. faecium* GIT colonization. For this purpose, *in vitro* experiments were performed and several existing models of GIT colonization were compared, while a novel one, as close as possible to human conditions, was developed for *in vivo* studies.

MATERIALS AND METHODS

Bacterial Strains

Data regarding the strain characteristics are summarized in **Table 1**. The *E. faecium* Aus0004 wild-type (WT) reference strain was used (Lam et al., 2012). This vancomycin-resistant (*vanB*-positive) clinical isolate was recovered from a bacteremic patient and belongs to the CC17. The MIC of amoxicillin for Aus0004 strain was 256 mg/l.

Three mutants were constructed to evaluate the role of Ern0160 in GIT colonization. As described by Zhang et al. (2011), an *ern0160*-deleted *E. faecium* Aus0004 mutant (named $\Delta 0160$) was constructed by allelic exchange with a truncated copy of the gene corresponding to 5'-3' positions of *ern0160* using pWS3 and specific primers (**Supplementary Table 1**). The *ern0160* gene with its native promoter and rho-independent terminator was cloned into the pAT29 shuttle vector using specific primers (Trieu-Cuot et al., 1990). The recombinant plasmid was introduced into *Escherichia coli* EC1000 and then into *E. faecium* $\Delta 0160$ (Leenhouts et al., 1996). The *trans*-complemented strain overexpressing *ern0160* was named $\Delta 0160_{0160}$. A strain $\Delta 0160$ with an empty pAT29 vector was used as control ($\Delta 0160_{pAT29}$). The transformants were selected on media containing 100 mg/l (*E. coli*) or 300 mg/l (*E. faecium*) of spectinomycin.

Bacterial Growth Curves and Competitive Assays

Growth curves were performed *in vitro* for each strain and WT was compared to $\Delta 0160$, while $\Delta 0160_{0160}$ was compared to $\Delta 0160_{pAT29}$. Strains were cultured aerobically overnight on Trypticase Soy (TS) agar (Thermo Fisher Scientific, Waltham, MA, United States) at $35 \pm 2^\circ\text{C}$. A colony was cultured in 10 ml of Brain Heart Infusion (BHI) broth (Thermo Fisher Scientific, Waltham, MA, United States) for 18 h at $35 \pm 2^\circ\text{C}$ under ambient air. Bacterial cultures were then adjusted to DO_{600} 0.1, and the bacterial growth was evaluated by DO_{600} at each time point (2, 3, 4, 5, 6, 9, and 24 h). Two competitive assays were also performed, WT versus $\Delta 0160$ and $\Delta 0160_{0160}$ versus $\Delta 0160_{pAT29}$. Strains were initially mixed at a ratio of 1:1, and bacterial growth was measured in the same way as described above. Spectinomycin was added (300 mg/l) to BHI and TS media

TABLE 1 | Bacterial strains and plasmids used in the study.

Strains or plasmids	Relevant characteristics	References
Strains		
<i>Enterococcus faecium</i>		
Aus0004 WT	<i>vanB</i> -positive <i>E. faecium</i> Aus0004 reference strain	Lam et al., 2012
Δ0160	<i>ern0160</i> -deleted Aus0004	This study
Δ0160_pAT29	Δ0160 carrying empty pAT29 vector	This study
Δ0160_Δ0160	Δ0160 carrying recombinant plasmid pAT29Ω0160	This study
<i>Escherichia coli</i>		
EC1000	Strain using for cloning	Leenhouts et al., 1996
Plasmids		
pWS3	Temperature-sensitive pG(+)-host9-derived shuttle vector used for gene disruption (Spc ^r)	Zhang et al., 2011
pAT29	High-copy-number shuttle vector used for cloning (Spc ^r)	Trieu-Cuot et al., 1990
pAT29Ωern0160	Recombinant pAT29 plasmid containing <i>ern0160</i> with its native promoter and rho-independent terminator (Spc ^r)	This study

Spc^r, spectinomycin resistance.

(BHI_{spec} and TS_{spec}) for all experiments with Δ0160_pAT29 and Δ0160_0160 strains to ensure the maintenance of the plasmid. For competitive assays, a sample of culture was plated on TS and TS_{spec} agar at each point of time, and each strain was identified by PCR, directly from colonies, under standard conditions and using specific primers (**Supplementary Table 1**). For each time point, 28 colonies were tested, and each experiment was performed independently three times.

Mouse Model of Gastrointestinal Tract Colonization

The same strains used for *in vitro* experiments were studied in *in vivo* protocols. For all the experiments, bacterial suspensions were calibrated as follows to inoculate mice with 10⁸ cfu/ml. Each strain was grown aerobically overnight on TS agar at 35 ± 2°C. A colony was cultured in 10 ml of BHI broth for 18 h at 35 ± 2°C under ambient air. After centrifugation (15 min, 3,500 rpm), the pellet was resuspended in 10 ml of 0.9% saline and centrifuged again. This second pellet was resuspended in 5 ml of 0.9% saline, and the inoculum was quantified by serial dilutions plated on TS agar. For co-colonization experiment, a suspension of each strain was prepared as described above, adjusted to the same OD₆₀₀, and mixed in a 1:1 ratio before being administered to mice. As previously, BHI_{spec} and TS_{spec} were used for all experiments with Δ0160_pAT29 and Δ0160_0160 strains. To ensure that mice GIT do not contain any *E. faecium*, an aerobic GIT microbiota study was performed on three cages of five mice. Ten fresh fecal pellets per cage, obtained by light abdominal massage, were suspended in 3 ml of 0.9% NaCl. This suspension was serially diluted and cultured on TS, BHI, and Bile Esculin Azide (BEA) agar plates (Sigma-Aldrich, Saint-Louis, MO, United States) aerobically at 35 ± 2°C for 24 h. The different colonies were then quantified and identified by MALDI-TOF mass spectrometry (Microflex, Bruker Daltonics, Billerica, MA, United States).


Six-week-old non-inbred female, specific pathogen-free, Swiss mice were purchased (Janvier Labs, Le Genest-Saint-Isle, France). Five animals were housed per cage, with controlled room temperature, a 12-h light–dark cycle, and sterile standard rodent

food and water ad libitum. Mice were acclimated for 1 week prior to the experiment. The experimental protocol was in keeping with French legislation on animal experimentation and approved by the Adaptive Therapeutics Animal Care and Use Committee (reference number: 2018010814547884-APAFIS#13479). To limit the bias induced by the natural murine coprophagia, mice were placed in a new cage on the day of administration of the bacterial suspension.

To compare antibiotic regimen efficacy, mice received antibiotics to decolonize GIT according to the different protocols described below. At day 0, mice were orally inoculated, with the bacterial suspension of *E. faecium* WT. To avoid standard gavage, 2 days before D0, a “water + chocolate spread” suspension was orally administered with a syringe to mice for them to get used to it. On the day of inoculation, chocolate spread was added to the bacterial suspension at the very last moment and orally administered to each mouse. GIT colonization was evaluated by quantifying *E. faecium* in fresh fecal pellet (one per mouse) obtained by gentle abdominal massage and collected in sterile tubes. Fecal pellets were collected before inoculation (D0) to ensure decolonization, and at days 3, 5, 7, 10, and 14 (**Figure 1**). Samples were weighted and homogenized in 1 ml of saline solution. Mice were euthanized with CO₂ at D14. Fecal pellets were quantitatively cultured onto TS and BEA agar plates for 18 h at 35 ± 2°C under ambient air, to quantify the aerobic flora and *E. faecium*, respectively. Bacterial loads were expressed in log₁₀ cfu/g of stool or tissue for each sample.

Before the *ern0160* study, the *in vivo* plasmid stability was verified by performing the protocol with Δ0160_pAT29 strain on five mice. Fecal pellets were collected at D3 and D10 and plated on agar with and without spectinomycin. The stability was evaluated by the percentage of colony containing the pAT29 plasmid, calculated by the ratio $\frac{cfu(TS_{spec})}{cfu(TS)}$.

For the *ern0160* study, the same protocol was performed with 15 mice per group. Mice received antibiotics before bacterial suspension administration. The suspension contained each strain alone (WT, Δ0160, Δ0160_0160, or Δ0160_pAT29) or a two-strain combination prepared as described above (WT + Δ0160 or Δ0160_0160 + Δ0160_pAT29). A fecal pellet for each animal



at D0, D3, D5, D7, and D10 were collected to be quantitatively cultured. Samples collected from mice colonized with WT or $\Delta 0160$ strains or the mixed suspension “WT + $\Delta 0160$ ” were cultured on TS and BEA agar. TS agar and TSspec agar were used to quantify bacterial load in samples collected from mice colonized with $\Delta 0160_{0160}$ or $\Delta 0160_{pAT29}$ strains and with the suspension “ $\Delta 0160_{0160}$ + $\Delta 0160_{pAT29}$.” All agar plates were incubated for 18 h at $35 \pm 2^\circ\text{C}$ under ambient air. For co-colonization assay, each strain was identified by PCR, directly from colonies, under standard conditions and using specific primers (**Supplementary Table 1**). Twelve colonies were tested for each sample.

Antibiotic Protocols

Five decolonization regimens were tested. Each protocol was administered to five mice before the inoculation at D0. Protocol A, described by Montealegre et al. (2016), combined SC clindamycin (Panpharma S.A., Luitré, France) injected every 12 h (2.4 mg/day/mouse) for 4 days and gentamicin (Panpharma) in DW (1 mg/ml) for 2 days before inoculation. Zhang et al. (2011) described protocol B, which combined SC ceftriaxone (Mylan, Canonsburg, PA, United States) and cefoxitin (Panpharma). Ceftriaxone (2.4 mg/day/mouse) was injected twice a day, 2 days before inoculation and cefoxitin (0.2 mg/ml) added to DW during the 14 days of the colonization. Protocol C was adapted from Heikens et al. (2009), who used SC ceftriaxone (2.4 mg/day/mouse) 2 days before inoculation and until the end of the study. In our adapted protocol, SC ceftriaxone was administered (2.4 mg/day/mouse) 2 days before inoculation and then in DW (0.1 mg/ml) until D14. Protocol D was the same as protocol B (ceftriaxone plus cefoxitin), with amoxicillin (Panpharma) (0.1 mg/ml) added in DW during the 2 days before inoculation. Finally, protocol E combined SC ceftriaxone (2.4 mg/day/mouse) and amoxicillin in DW (0.1 mg/mL) 2 days before inoculation; ceftriaxone (0.1 mg/ml) and amoxicillin (0.03 mg/ml) were then put in DW throughout the colonization.

All regimens are summarized in **Figure 2**. One group received no antibiotics as a control group.



Statistical Analysis

For competitive and co-colonization assays, competitive index (CI) and normalized competitive index (nCI) were calculated for each time point as follows. CI was the ratio between “ $\Delta 0160$ colonies” and “WT colonies,” or between “ $\Delta 0160_{0160}$ colonies” and “ $\Delta 0160_{pAT29}$ colonies.” nCI was calculated by dividing CI by CI calculated at T0 for *in vitro* assay, and D0 (suspension inoculated) for *in vivo* experiments. A normalized competitive index of 1 meant no difference, a normalized competitive index < 1 meant that WT or $\Delta 0160_{pAT29}$ was in higher numbers than $\Delta 0160$ or $\Delta 0160_{0160}$, respectively, and a competitive index > 1 meant that $\Delta 0160$ or $\Delta 0160_{0160}$ was in higher numbers than WT or $\Delta 0160_{pAT29}$, respectively. A Shapiro–Wilk test (p value > 0.05) was used to evaluate normality. According to the result, CIs were analyzed using Student’s *t* test or Wilcoxon signed-rank test, with the null hypothesis: mean CI was not significantly different from 1 (p values of 0.05 used). Between-group cfu counts for fecal pellets were expressed by mean and standard deviation and compared with the Mann–Whitney test or Student’s *t* test. Antibiotic protocol results were analyzed using a Kruskal–Wallis test. $p < 0.05$ was considered statistically significant. Data were analyzed using GraphPad Prism 7 (GraphPad Software, Inc.).

RESULTS

In vitro Experiments

Results for all bacterial growth curves are represented in **Figures 3A,B**. No significant difference was observed between WT and $\Delta 0160$ growth curves. The maximum DO_{600} was similar and achieved simultaneously. Conversely, $\Delta 0160_{0160}$ and $\Delta 0160_{pAT29}$ showed a different growth rate. A difference of approximately 2 h to reach the growth plateau was observed



between the two strains, and $\Delta 0160_{0160}$ grew more slowly than $\Delta 0160_{pAT29}$. Moreover, the maximum DO_{600} was lower for $\Delta 0160_{0160}$ bacterial growth.

According to these results, only the WT and $\Delta 0160$ strains were studied in competitive assays. A competitive assay was conducted during 24 h with PCR on 28 different colonies

performed at each point of time. Results are reported in **Figures 3C,D**. Up to 9 h of culture, the nCI was not significantly different from 1, which means that the two strains were growing in a similar way. At T24, the mean nCI was 0.57 and significantly lower than 1 ($p = 0.02$), meaning that the WT strain was predominant compared to the deleted strain Δ 0160.

In vivo Experiments

Experimental Model Development

Each protocol was tested on five mice and colonized with the *E. faecium* WT suspension for 14 days. Prior to beginning of our experiments, normal aerobic GIT microbiota of Swiss mice was determined on five mice. It was composed of lactobacilli (85.2%), Enterobacterales (8.5%), and *E. faecalis* (6.3%). For each experiment, mice were screened for *E. faecium* before colonization (D0) and no stool samples contained any.

Results are shown in **Figure 4**. In the control group, which received no antibiotic prior to WT suspension administration, no VREF were isolated from fecal pellets at D3, 5, 7, 10, and 14. With protocol A (gentamicin + clindamycin), fecal pellets contained a mean of 3.34×10^9 cfu/g at D3, 4.24×10^8 cfu/g at D5, and 3.00×10^7 cfu/g at D7. No VREF were found between D10 and D14. Whereas there were no *E. faecalis* at D0, they were gradually detected from D7 to D14 (3.08×10^4 cfu/g at D14). With protocols B (ceftriaxone + ceftiofloxacin), C (ceftriaxone alone), D (ceftriaxone + ceftiofloxacin + amoxicillin), and E (ceftriaxone + amoxicillin), a high and stable colonization was observed. Between D3 and D14, fecal pellets from mice treated with protocols B and C contained a mean of 8.86×10^9 cfu/g and 5.50×10^9 cfu/g, respectively. Some *E. faecalis* were detected at the end of colonization, but they remained a minority compared to VREF. The mean VREF bacterial load in fecal pellets from animals receiving protocols D and E antibiotics were 8.89×10^9 and 6.69×10^9 cfu/g, respectively. No contamination by *E. faecalis* was observed with protocol E. Regarding VREF colonization, no significant difference was observed between protocols B, C, D, and E ($p = 0.6$).




FIGURE 4 | VREF bacterial load in fecal pellets according to antibiotic regimen and time. Each point represents the mean value of cfu values per gram obtained from five mice. A Clindamycin SC + gentamicin DW, B ceftriaxone SC + ceftiofloxacin DW, C ceftriaxone SC + DW, D ceftriaxone SC + amoxicillin DW + ceftiofloxacin DW, and E ceftriaxone + amoxicillin SC and DW (SC, subcutaneous; DW, drinking water).

Ern0160 Study


To study *in vivo* the role of Ern0160 in GIT colonization, the model with protocol E (ceftriaxone plus amoxicilline) was applied during 10 days, with each strain alone in a first step (WT, Δ 0160, Δ 0160_0160, or Δ 0160_pAT29) and with a combination of two in a second step (WT + Δ 0160 and Δ 0160_0160 + Δ 0160_pAT29). Each group was composed of 15 mice. The *in vivo* stability was first evaluated by determining the percentage of colony that retained the pAT29 plasmid. At D3, 94% of colonies retained the plasmid and 75% at D10, which is consistent with studies previously published (Deol et al., 2007).

Results obtained with GIT colonization with single strains are shown in **Figures 5A,B**. At D3, the mean bacterial load was significantly higher with the WT strain compared to Δ 0160 (5.2×10^9 cfu/g and 2.8×10^9 cfu/g, respectively, $p = 0.008$). Then, from D5 to D10, GIT colonization remained high and stable with WT and Δ 0160 strains, with a mean bacterial load of 5.78×10^9 and 6.03×10^9 cfu/g, respectively, which was not significantly different (**Figure 5A**). A high and stable GIT colonization was also obtained from D3 with mutant strains Δ 0160_0160 and Δ 0160_pAT29. At D3, the mean bacterial load was 1.49×10^9 and 1.61×10^9 cfu/g with Δ 0160_0160 and Δ 0160_pAT29, respectively, which was not significantly different. From D5 to D10, GIT colonization remained stably high with Δ 0160_0160 and Δ 0160_pAT29 strains, with a mean bacterial load of 5.93×10^9 and 1.70×10^9 cfu/g, respectively, which was not significantly different (**Figure 5B**).

The co-colonization model was performed with the two combinations of strains. With WT + Δ 0160 suspension, the nCI was not significantly different from 1 at D3; the two strains colonized GIT in the same way. From D5 to D10, nCI significantly decreased ($p = 0.01$ at D5, and $p < 0.01$ at D7 and D10) with a predominance of the WT strain (**Figures 5C,D**). With Δ 0160_0160 + Δ 0160_pAT29 suspension, an nCI under 0.1 was observed from D3 to the end of the protocol for all mice. At D10, all colonies tested belonged to the Δ 0160_pAT29 strain and no Δ 0160_0160 colony was isolated.

DISCUSSION

In the last decade, bacterial sRNAs have been more and more investigated, and even if functions of many of these riboregulators are still unknown, several of them are involved in stress response or virulence. Few data are available on sRNAs in *E. faecium*; indeed, they have been identified only recently (Siné et al., 2017). In their study, Siné et al. showed that the expression level of one sRNA, Ern0160, was significantly downregulated under SIC daptomycin exposure. More recently, Dejoies et al. (2021) described a significant reduction in *ern0160* expression level under SICs of biocides. These two studies suggest that Ern0160 could be involved in antibiotic and biocide stress responses in *E. faecium*, and for these reasons, it appeared to be an interesting candidate potentially involved in its pathogenicity. GIT colonization is the main starting point of VREF infection and hospital outbreaks. Colonization



mechanisms remain unclear, so this study sought to highlight whether *Ern0160* could be implicated.

GIT colonization studies are difficult to reproduce *in vitro* because many parameters are involved, such as pH, cell diversity, or enzymatic activity. Experimental models have been developed to study enterococcus infectious diseases since 1899 (Maccallum and Hastings, 1899). These models enabled researchers to study enterococcal pathogenesis in the context of the innate and adaptive immune responses, as closely as possible to human conditions. Moreover, experimental models are reproducible and reliable statistical analysis on data could be done. Mice are the most frequently used animal to study enterococci in GIT (Goh et al., 2017). In our study, we evaluated for the first time sRNA of *E. faecium* in a GIT colonization model optimized for this purpose. Several models of GIT colonization have been published, based on the administration of a suspension of enterococci *via* oral gavage or in the drinking water. Oral gavage is an invasive procedure that can damage the esophagus, but a calibrated quantity of bacteria could be administered. Because mice are housed by five, if the bacterial suspension is administered in the drinking water, the number of bacteria taken

up by each mouse is not precisely quantifiable. Because of these disadvantages, an alternative method has been chosen for our study (Scarborough et al., 2020). A “water+chocolate spread” solution was orally administered to mice a few days before starting colonization and then added to bacterial suspension. Thus, a calibrated suspension of bacteria could be administered without invasive procedure and thus avoid the possible associated complications. Prior to inoculation, mice received antibiotics to eliminate GIT normal flora. Several antibiotic regimens have been published and compared in our study. All tested protocols led to an important colonization but had some limitations. With the one associating clindamycin and gentamicin, the VREF colonization did not persist long enough and with protocols composed of β -lactams without amoxicillin, a significant growth of *E. faecalis* was observed. A high and stable colonization without *E. faecalis* contamination was obtained with two regimens, ceftriaxone associated with amoxicillin and ceftriaxone associated with amoxicillin and ceftioxin. As ceftioxin is not frequently used in human medicine unlike ceftriaxone, the protocol without ceftioxin was preferred, to be as close as possible to human conditions.

In our *in vitro* experiments, the deleted mutant strain Δ 0160 grew like the wild-type strain. These results have been confirmed in *in vivo* experiments. Indeed, a similar colonization profile was obtained with the two strains tested individually. Competitive assays have also been performed *in vitro* and *in vivo*. *In vitro*, neither of the two strains grew more than the other up to 24 h of culture. At 24 h, the wild-type strain was slightly predominant. As *in vitro* experiments were performed in BHI broth, which is far from the composition of the digestive tract, it was important to perform competition assays in mice. In the co-colonization model, the wild-type strain was significantly predominant from day 3 until the end of the protocol. These results suggested that Ern0160 could be involved in the GIT colonization process. To complete the results obtained with the deleted strain, identical *in vitro* and *in vivo* experiments were performed with the *trans*-complemented strain Δ 0160_0160, which overexpressed *ern0160*, knowing that overexpression experiments are classically used to study sRNA functions (Brantl and Jahn, 2015). The strain Δ 0160_pAT29, with an empty pAT29 vector, was used as control to compare strains with supposed similar fitness costs. In individual bacterial growth curve assays, the Δ 0160_0160 strain appeared to grow more slowly than the Δ 0160_pAT29 strain. The overexpression of *ern0160* by the strain Δ 0160_0160 may induce an energetic cost for the bacterium and could therefore explain the shift observed in growth kinetics. In the colonization model with only a strain, the two strains colonized mice in the same way during all protocol. In the co-colonization model, the Δ 0160_pAT29 strain was largely predominant by day 3 and until the end of the protocol. Based on our first results, it would have been expected that the complemented strain Δ 0160_0160 would colonize GIT more than the Δ 0160_pAT29 strain. As the Δ 0160_0160 strain overexpressed *ern0160* compared to the WT strain, these results suggested that an overexpression of *ern0160* could be deleterious to the strain in GIT colonization. Altogether, these findings show the involvement of Ern0160 in GIT colonization with a probable very tight regulation. Further studies, in particular with a *cis*-complemented strain, may provide additional information. As Ern0160 has probably pleiotropic effects, it will also be important to determine which targets are regulated by Ern0160 to understand precisely molecular mechanisms. As the different pathways of adaptation or virulence often involve several RNAs, it will also be interesting to determine if other sRNAs are involved in GIT colonization and if there is a cross-regulation with Ern0160. This study was the first to explore

in vivo *E. faecium* regulatory RNAs and its potential function in GIT colonization. Further studies are needed to determine the targets of this sRNA in order to decipher its role and regulatory circuits.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by Adaptive Therapeutics Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS

SR, BF, VC, and MR conceived and designed the experiments, analyzed the data, and wrote the manuscript. SR, KL, VB, LD, and AL performed the experiments. VB, BF, VC, and MR contributed with reagents, materials, and analysis tools. All the authors discussed the results and commented on the manuscript.

FUNDING

This work was supported by the “Fondation pour la Recherche Médicale” (to SR, grant number FDM 20170637920), the “Institut National de la Santé et de la Recherche Médicale,” and Rennes 1 University.

ACKNOWLEDGMENTS

We thank the Biosit Arche platform (Rennes 1 University, France), for animal house facilities.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2021.757227/full#supplementary-material>

REFERENCES

- Brantl, S., and Jahn, N. (2015). sRNAs in bacterial type I and type III toxin-antitoxin systems. *FEMS Microbiol. Rev.* 39, 413–427. doi: 10.1093/femsre/fuv003
- Cattoir, V., and Giard, J.-C. (2014). Antibiotic resistance in *Enterococcus faecium* clinical isolates. *Expert Rev. Anti Infect. Ther.* 12, 239–248. doi: 10.1586/14787210.2014.870886
- Dejoes, L., Le Neindre, K., Reissier, S., Felden, B., and Cattoir, V. (2021). Distinct expression profiles of regulatory RNAs in the response to biocides in *Staphylococcus aureus* and *Enterococcus faecium*. *Sci. Rep.* 11:6892. doi: 10.1038/s41598-021-86376-y
- Deol, P., Zaiss, D. M. W., Monaco, J. J., and Sijts, A. J. A. M. (2007). Rates of processing determine the immunogenicity of immunoproteasome-generated epitopes. *J. Immunol.* 178, 7557–7562. doi: 10.4049/jimmunol.178.12.7557
- Donskey, C. J., Hanrahan, J. A., Hutton, R. A., and Rice, L. B. (2000). Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant *Enterococcus faecium* in the mouse gastrointestinal tract. *J. Infect. Dis.* 181, 1830–1833. doi: 10.1086/315428
- Donskey, C. J., Hoyen, C. K., Das, S. M., Farmer, S., Dery, M., and Bonomo, R. A. (2001). Effect of oral *Bacillus coagulans* administration on the density of vancomycin-resistant enterococci in the stool of colonized mice. *Lett. Appl. Microbiol.* 33, 84–88. doi: 10.1046/j.1472-765X.2001.00948.x

- Dubin, K., and Pamer, E. G. (2014). Enterococci and their interactions with the intestinal microbiome. *Microbiol. Spectr.* 5. doi: 10.1128/microbiolspec.BAD-0014-2016
- European Centre for Disease Prevention and Control (2019). *Surveillance of Antimicrobial Resistance in Europe 2018*. Stockholm: ECDC, 110.
- Eyraud, A., Tattevin, P., Chabelskaya, S., and Felden, B. (2014). A small RNA controls a protein regulator involved in antibiotic resistance in *Staphylococcus aureus*. *Nucleic Acids Res.* 42, 4892–4905. doi: 10.1093/nar/gku149
- Goh, H. M. S., Yong, M. H. A., Chong, K. K. L., and Kline, K. A. (2017). Model systems for the study of enterococcal colonization and infection. *Virulence* 8, 1525–1562. doi: 10.1080/21505594.2017.1279766
- Heikens, E., Leendertse, M., Wijnands, L. M., van Luit-Asbroek, M., Bonten, M. J., Poll, T., et al. (2009). Enterococcal surface protein Esp is not essential for cell adhesion and intestinal colonization of *Enterococcus faecium* in mice. *BMC Microbiol.* 9:19. doi: 10.1186/1471-2180-9-19
- Klein, G., and Raina, S. (2017). Small regulatory bacterial RNAs regulating the envelope stress response. *Biochem. Soc. Trans.* 45, 417–425. doi: 10.1042/BST20160367
- Lam, M. M. C., Seemann, T., Bulach, D. M., Gladman, S. L., Chen, H., Haring, V., et al. (2012). Comparative analysis of the first complete *Enterococcus faecium* genome. *J. Bacteriol.* 194, 2334–2341. doi: 10.1128/JB.00259-12
- Lebreton, F., van Schaik, W., McGuire, A. M., Godfrey, P., Griggs, A., Mazumdar, V., et al. (2013). Emergence of epidemic multidrug-resistant *Enterococcus faecium* from animal and commensal strains. *mBio* 4, e00534–13. doi: 10.1128/mBio.00534-13
- Leenhouts, K., Buist, G., Bolhuis, A., Ten Berge, A., Kiel, J., Mierau, I., et al. (1996). A general system for generating unlabelled gene replacements in bacterial chromosomes. *Mol. Gen. Genet.* 253, 217–224. doi: 10.1007/s004380050315
- Maccallum, W. G., and Hastings, T. W. (1899). A case of acute endocarditis caused by *Micrococcus zymogenes* (nov. spec.), with a description of the microorganism. *J. Exp. Med.* 4, 521–534.
- Michaux, C., Hartke, A., Martini, C., Reiss, S., Albrecht, D., Budin-Verneuil, A., et al. (2014). Involvement of *Enterococcus faecalis* small RNAs in stress response and virulence. *Infect. Immun.* 82, 3599–3611. doi: 10.1128/IAI.01900-14
- Montealegre, M. C., Singh, K. V., and Murray, B. E. (2016). Gastrointestinal tract colonization dynamics by different *Enterococcus faecium* clades. *J. Infect. Dis.* 213, 1914–1922. doi: 10.1093/infdis/jiv597
- Mraheil, M. A., Billion, A., Kuenne, C., Pischmarov, J., Kreikemeyer, B., Engelmann, S., et al. (2010). Comparative genome-wide analysis of small RNAs of major Gram-positive pathogens: from identification to application. *Microb. Biotechnol.* 3, 658–676. doi: 10.1111/j.1751-7915.2010.00171.x
- O'Driscoll, T., and Crank, C. W. (2015). Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. *Infect. Drug Resist.* 8, 217–230. doi: 10.2147/IDR.S54125
- Scarborough, J., Mueller, F., Arban, R., Dorner-Ciossek, C., Weber-Stadlbauer, U., Rosenbrock, H., et al. (2020). Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders. *Brain Behav. Immun.* 88, 461–470. doi: 10.1016/j.bbi.2020.04.015
- Sinel, C., Augagneur, Y., Sassi, M., Bronsard, J., Cacaci, M., Guérin, F., et al. (2017). Small RNAs in vancomycin-resistant *Enterococcus faecium* involved in daptomycin response and resistance. *Sci. Rep.* 7:11067. doi: 10.1038/s41598-017-11265-2
- Trieu-Cuot, P., Carlier, C., Poyart-Salmeron, C., and Courvalin, P. (1990). A pair of mobilizable shuttle vectors conferring resistance to spectinomycin for molecular cloning in *Escherichia coli* and in gram-positive bacteria. *Nucleic Acids Res.* 18:4296. doi: 10.1093/nar/18.14.4296
- Ubeda, C., Taur, Y., Jenq, R. R., Equinda, M. J., Son, T., Samstein, M., et al. (2010). Vancomycin-resistant *Enterococcus* domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. *J. Clin. Invest.* 120, 4332–4341. doi: 10.1172/JCI43918
- Wagner, E. G. H., and Romby, P. (2015). “Chapter three—small RNAs in bacteria and archaea: who they are, what they do, and how they do it,” in *Advances in Genetics*, eds T. Friedmann, J. C. Dunlap, and S. F. Goodwin (Cambridge, MA: Academic Press), 133–208. doi: 10.1016/bs.adgen.2015.05.001
- Weiner-Lastinger, L. M., Abner, S., Edwards, J. R., Kallen, A. J., Karlsson, M., Magill, S. S., et al. (2020). Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015–2017. *Infect. Control Hosp. Epidemiol.* 41, 1–18. doi: 10.1017/ice.2019.296
- Zhang, X., Top, J., de Been, M., Bierschenk, D., Rogers, M., Leendertse, M., et al. (2013). Identification of a genetic determinant in clinical *Enterococcus faecium* strains that contributes to intestinal colonization during antibiotic treatment. *J. Infect. Dis.* 207, 1780–1786. doi: 10.1093/infdis/jit076
- Zhang, X., Vrijenhoek, J. E. P., Bonten, M. J. M., Willems, R. J. L., and van Schaik, W. (2011). A genetic element present on megaplasmids allows *Enterococcus faecium* to use raffinose as carbon source. *Environ. Microbiol.* 13, 518–528. doi: 10.1111/j.1462-2920.2010.02355.x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Reissier, Le Neindre, Bordeau, Dejoies, Le Bot, Felden, Cattoir and Revest. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.